Avacta Group plc, a life sciences company focused on targeted cancer treatments and diagnostics, has provided a block listing six-monthly return. The company has an EMI scheme, with a balance of unallotted securities of 797,922 at the end of the period. The scheme has been increased by 600,000 since the last return, and 216,256 securities have been issued/allotted during the period. Avacta also has an LTIP scheme, with a balance of unallotted securities of 5,277,257 at the end of the period. The scheme has been increased by 3,700,000 since the last return, and 793,332 securities have been issued/allotted during the period.
Avacta Group is a UK-based company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The company has two divisions: an oncology biotech division and a diagnostics division. The oncology biotech division develops novel, highly targeted cancer drugs using proprietary therapeutic platforms. The diagnostics division is executing an M&A led growth strategy to create a full-spectrum diagnostics business. Avacta's proprietary platforms, Affimer® and pre|CISION™, underpin its cancer therapeutics and diagnostics divisions. The pre|CISION™ platform modifies chemotherapy to be activated only in the tumor tissue, reducing systemic exposure and toxicity. The lead pre|CISION™ program, AVA6000, is in Phase 1 studies and has shown improved safety compared to standard doxorubicin. The Affimer® platform is used to develop advanced immunotherapies and improve the performance of immunodiagnostics.